Transplant Rejection clinical trials

Explore recruiting transplant rejection clinical trials.

Recruiting transplant rejection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Transplant Rejection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multi-cohort, randomized, Phase 2, open-label study to assess the preliminary efficacy, safety, and pharmacokinetics of BIVV020 for prevention and treatment of antibody- mediated rejection in adult kidney transplant recipients

Sweden, Germany, Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients

Germany, Hungary, Italy, Belgium, Czechia, Finland +6 more

Phase II and Phase III (Integrated) EU CTIS Study details

Long-Term Follow-Up of Patients Who Have Received An Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR-Treg therapy, TX200-TR101) In A Prior Clinical study

Belgium, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non-comparative registry and concurrent reference cohorts

Germany, Sweden, Belgium, Czechia, Austria, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A prospective, post-authorisation long-term follow up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort

Spain, Czechia, Belgium, Sweden, France, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Crossover study to investigate the safety and tolerability as well as the blood levels after three single doses of Tacrolimus, of which 2 are administered via the cheek mucosa and 1 dose via the mouth (oral).

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Transplant Rejection trials by city

Transplant Rejection in Toronto Transplant Rejection in Vancouver Transplant Rejection in Montreal Transplant Rejection in Calgary Transplant Rejection in Edmonton Transplant Rejection in Ottawa Transplant Rejection in Winnipeg Transplant Rejection in Quebec City Transplant Rejection in Hamilton Transplant Rejection in Kitchener Transplant Rejection in London Transplant Rejection in Halifax Transplant Rejection in New York Transplant Rejection in Los Angeles Transplant Rejection in Chicago Transplant Rejection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease